EZH2 in normal hematopoiesis and hematological malignancies

Area of Science:

• Biochemistry
• Molecular Biology
• Hematology

Background:

• Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2.
• EZH2 regulates gene expression via histone H3 lysine 27 methylation.
• EZH2 plays key roles in normal hematopoietic stem cell and B cell differentiation.

Purpose of the Study:

• To review the functions of EZH2 in normal and pathological hematological processes.
• To summarize recent advancements in developing EZH2 inhibitors for hematological malignancies.

Main Methods:

• Literature review of EZH2's role in hematopoiesis and cancer.
• Analysis of current EZH2 inhibitor development and therapeutic potential.

Main Results:

• EZH2 deregulation is implicated in various hematological malignancies.
• Targeted small molecules inhibiting EZH2 have been developed.
• These inhibitors are under evaluation for personalized cancer treatment.

Conclusions:

• EZH2 is a critical regulator in both normal and malignant hematopoiesis.
• EZH2 inhibitors represent a promising therapeutic strategy for hematological cancers.
• Further research is needed to fully evaluate their clinical efficacy.